Sana Biotechnology

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SEATTLE, April 24, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that management will host a Research & Development (R&D) Day on Thursday, May 23, 2023 from 9:00 a.m. – 12:00 p.m. ET in New York, NY.

Sana Biotechnology to Host Research & Development Day

Axsome Therapeutics

CRISPR Therapeutics

Investors may want to keep an eye on the biotech boom and these top biotech stocks to watch. For one, the sector is still one of the safest, most recession-proof investments around.

The Top 3 Biotech Stocks to Watch in 2023

Hypoimmune-modified CD19-directed CAR T cells persist and remain functional in preclinical models over multiple months in an allogeneic humanized immune system, even with tumor re-challenge

Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting

The average of price targets set by Wall Street analysts indicates a potential upside of 78.2% in Sana (SANA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Sana (SANA) Have the Potential to Rally 78.23% as Wall Street Analysts Expect?

Sana Biotechnology Is Technically Overbought So Buy It Later

Brookdale Senior Living

The week that ended April 14 was a good one for markets overall and a great one for two stocks in the healthcare sector. Sana Biotechnology jumped 58% higher last week as investors cheered preclinical results for its lead candidates.

2 Growth Stocks That Jumped 42% and 58% Last Week: Can They Still Climb Higher?

Sana Biotechnology is developing a cell-editing platform that it hopes will be able to avoid immune-system rejection. The company has no revenue but enough cash to fund operations into 2025, it said.

Why Shares of Sana Biotechnology Jumped This Week

Hypoimmune-modified allogeneic CD19-directed CAR T cells can evade immune detection and kill tumor cells in a novel humanized allogeneic preclinical model in vivo, including following tumor cell reinjection

Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses

Hypoimmune human islet cells normalized glucose in diabetic humanized immunocompetent mouse model and avoided allogeneic and autoimmune rejection by the immune system

Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded Allogeneic and Autoimmune Rejection and Controlled Type 1 Diabetes in Preclinical Model

Dr. Douglas E. Williams as Head of Research and Development Dr. Gary Meininger as Chief Medical Officer SEATTLE, April 10, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointments of two senior leaders to its research and development organization, Douglas E.

Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization

Announced SC291 IND clearance with goal to report initial clinical data this year

Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Late-breaking poster presentation to highlight preclinical data demonstrating that the increased potency of CD8-targeted fusosomes enhances CAR gene delivery to resting primary T cells Late-breaking poster presentation to highlight preclinical data demonstrating that the increased potency of CD8-targeted fusosomes enhances CAR gene delivery to resting primary T cells

Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting

SEATTLE, March 01, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Cowen 43rd Annual Health Care Conference at 9:50 a.m. ET on Wednesday, March 8, 2023. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

Sana Biotechnology to Present at the Cowen 43rd Annual Health Care Conference

It's a challenging time for biotechs needing cash. Sana Biotechnology is such a company from the stable of Boston-based Flagship Pioneering.

Sana Biotechnology: Time And Cash Burn Are The Enemies

Sana had its first clinical trial cleared for initiation by the FDA in January. The current stock price is way below the 2021 IPO price.

Sana Biotechnology A Buy On Low Price And First IND

SEATTLE, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Guggenheim Healthcare Talks 5th Annual Oncology Conference at 1:00 p.m. ET on Thursday, February 9, 2023. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

Sana Biotechnology to Present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference

Gossamer Bio Inc

Rite Aid

Canoo

Are these penny stocks ready to squeeze? The post 4 Penny Stocks To Watch With High Short Interest In January 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Watch With High Short Interest In January 2023

Goal is to report initial SC291 clinical data this year

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies

Aytu BioScience

Ginkgo Bioworks Holdings

PLBY Group

Short squeeze penny stocks to watch this month. The post 4 Short Squeeze Penny Stocks To Watch In January 2023; Time To Buy?

4 Short Squeeze Penny Stocks To Watch In January 2023; Time To Buy?

SEATTLE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the 41st Annual J.P. Morgan Healthcare Conference at 3:45 p.m. PT on Tuesday, January 10, 2023. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare Conference

Transplanted hypoimmune (HIP)-modified allogeneic CD19-targeted CAR T cells control CD19+ tumor cells in fully immunocompetent allogeneic humanized mice, evading both the adaptive and innate immune systems

Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual Meeting

Seattle-based cell and gene therapy company Sana Biotechnology will reduce its workforce by 15%, according to a statement issued Tuesday.

Sana Biotechnology will cut 15% of its workforce in latest layoffs affecting Seattle companies

Expect to file IND this year for SC291 with potential clinical data in 2023

Sana Biotechnology Confirms Key Program Timelines and Announces Portfolio Prioritization

SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that six abstracts have been accepted for presentation, including two oral presentations, at the 64th American Society of Hematology (ASH) Annual Meeting to be held December 10-13, 2022 in New Orleans, LA.

News for Sana Biotechnology Stock (SANA)